Evidence map›Paper›PMID 41472508›Full record

ArticleAmerican journal of hematology2026

Proteomic Analysis of Golden Sputum Reveals Pulmonary Complement Activation During Acute Chest Syndrome in Children With Sickle Cell Disease.

Slimane Allali, Nabiha Sbeih, Rachel Rignault-Bricard, Johanna Bruce, Morgane Le Gall, Claire Heilbronner, Noemie de Cacqueray, Sofia Angyalosy, Melissa Taylor, Joséphine Brice and 5 more

Abstract read
In one paragraph

Article in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Slimane AllaliDepartment of General Pediatrics and Pediatric Infectious Diseases, Sickle Cell Center, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.ORCID 0000-0001-7068-4530
Nabiha SbeihLaboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Université Paris Cité Imagine Institute, Inserm U1163, Paris, France.
Rachel Rignault-BricardLaboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Université Paris Cité Imagine Institute, Inserm U1163, Paris, France.
Johanna BruceProteom'IC Facility, Université Paris Cité, CNRS, INSERM, Institut Cochin, Paris, France.
Morgane Le GallProteom'IC Facility, Université Paris Cité, CNRS, INSERM, Institut Cochin, Paris, France.
Claire HeilbronnerDepartment of Pediatric Intensive Care, Necker-Enfants Malades Hospital, AP-HP, Université Paris Cité, Paris, France.ORCID 0000-0002-0595-5944
Noemie de CacquerayDepartment of Pediatric Intensive Care, Necker-Enfants Malades Hospital, AP-HP, Université Paris Cité, Paris, France.
Sofia AngyalosyDepartment of Pediatric Intensive Care, Necker-Enfants Malades Hospital, AP-HP, Université Paris Cité, Paris, France.
Melissa TaylorDepartment of General Pediatrics and Pediatric Infectious Diseases, Sickle Cell Center, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
Joséphine BriceDepartment of General Pediatrics and Pediatric Infectious Diseases, Sickle Cell Center, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
Mariane de MontalembertDepartment of General Pediatrics and Pediatric Infectious Diseases, Sickle Cell Center, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.ORCID 0000-0002-4900-4753
Martina BevacquaDepartment of General Pediatrics and Pediatric Infectious Diseases, Sickle Cell Center, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
Emilie-Fleur GautierProteom'IC Facility, Université Paris Cité, CNRS, INSERM, Institut Cochin, Paris, France.ORCID 0000-0002-0394-6606
Olivier HermineLaboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Université Paris Cité Imagine Institute, Inserm U1163, Paris, France.
Thiago Trovati MacielLaboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Université Paris Cité Imagine Institute, Inserm U1163, Paris, France.ORCID 0000-0002-9347-981X

Funding

Agence Nationale de la Recherche under the Investissements d'avenir Program ANR-10-IAHU-01France 2030 Program Through the Idex Université Paris Cité, InIdex GR-Ex ANR-18-IDEX-0001
6 · The paper itself

Abstract

Acute chest syndrome (ACS) is one of the most common severe complications of sickle cell disease (SCD). In recent years, a major role of inflammation and innate immunity has been evidenced, but ACS pathophysiology remains incompletely understood, and therapeutic options are limited. We performed proteomic analysis of induced sputum and tracheal aspirates in eight SCD children during ACS (four intubated and four non-intubated) and in three during vaso-occlusive crisis (VOC) without ACS. Proteomic analysis revealed that one of the main canonical pathways involved during ACS was the complement system. To further investigate its implication, we measured the main components of the complement alternative and terminal pathways in sputum and plasma from SCD children during 27 ACS episodes compared with 16 VOC episodes without ACS. A dramatic increase in the median level of C3a, C5a, sC5b-9, factor B, factor D, properdin, and factor H was observed in the sputum from SCD children during ACS. In the plasma, no significant increase was observed during ACS compared to VOC, except for sC5b-9, whose median level was twofold higher than during VOC but 16-fold lower than the sC5b-9 median level in the sputum during ACS. Also, the C3a/C3 and C5a/C5 ratios were significantly increased in sputum compared to plasma during ACS, reflecting a predominant local pulmonary activation of the complement system compared to systemic activation. Our results reveal the potentially crucial role of complement activation in the lungs during ACS and open new therapeutic perspectives with anti-complement agents for this severe complication of SCD.

Indexed as

Acute Chest SyndromeAnemia, Sickle CellComplement ActivationLungProteomicsSputumAdolescentChildChild, PreschoolComplement System ProteinsFemaleHumansMaleComplement System Proteinsacute chest syndromechildcomplement activationsickle cell diseasesputum

Identifiers

PMID41472508
PMCPMC12994127

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.